Bayhill Therapeutics Files For IPO
Palo Alto-based BayHill Therapeutics, a firm that develops biopharmaceuticals for the treatment of autoimmune diseases, filed for an IPO today. According to a filing with the SEC, Bayhill is looking to raise up to $86.25M in an IPO on the Nasdaq Global Market as BHTX. The firm's IPO is being underwritten by Pacific Growth Equities, Lazard Capital Markets, Merriman Curhan Ford & Co., and Punk, Ziegel & Company. Bayhill is venture backed by US Venture PArtners, Morgenthaler Partners, De Novo Ventures, CMEA Ventures, Eli Lilly, Latterell Venture Partners, and Montreux Equity Partners.
posted on Wednesday, January 9, 2008
Related companies:
Bayhill Therapeutics
Related stories:
> ARYx Therapeutics Files For IPO
> Merck Buys Sirna Therapeutics
> Iconic Therapeutics Finds $20M
> Hyperion Therapeutics Files For IPO
> PEAR Therapeutics Gets $50M For Treating Substance Abuse With Software
silicontap.com Home